Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K31/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20210128532HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS
US 06.05.2021
Int.Class A61K 31/4192
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
41921,2,3-Triazoles
Appl.No 17081940 Applicant GyanRx Sciences, Inc. Inventor Julian A. Codelli

The present disclosure relates generally to modulators of human glycolate oxidase enzyme and methods of use and manufacture thereof.

2.20210128658HIGH YIELD EXTRACTION METHOD FOR AND PRODUCTS OF KANNA PLANTS
US 06.05.2021
Int.Class A61K 36/185
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18Magnoliophyta (angiosperms)
185Magnoliopsida (dicotyledons)
Appl.No 17093937 Applicant Plant Synergy Inc. Inventor Armand Bytton

A composition is produced by a method of extracting a Kanna plant, wherein the method comprises the steps of harvesting and drying the plant, extracting the alkaloids comprising Mesembrine from the plant in a solvent, and filtering the solvent-Kanna plant mixture to remove the solvent and extracted alkaloids from a spent Kanna plant matter. The method further includes drying the spent Kanna plant matter, purifying and separating the extracted alkaloids from the solvent, and mixing the extracted alkaloids back into the dried spent plant matter.

3.20210130473TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF
US 06.05.2021
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No 17066897 Applicant Silverback Therapeutics, Inc. Inventor Peter R. BAUM

Various conjugates and compositions thereof are disclosed for use in the treatment of a liver disease, such as liver cancer and liver fibrosis. The compositions comprise conjugates, wherein the conjugates are comprised of an antibody or antibody construct specific for ASGR1 or ASGR2 attached to a TGFβR1 inhibitor via a linker. Additionally provided are the methods of preparation of the conjugates and compositions thereof.

4.20210128452COMPOSITIONS AND METHODS OF IMPROVING THE SKIN MICROBIOME
US 06.05.2021
Int.Class A61K 8/99
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
8Cosmetics or similar toilet preparations
18characterised by the composition
96containing materials, or derivatives thereof, of undetermined constitution
99from microorganisms other than algae or fungi, e.g. protozoa or bacteria
Appl.No 17089469 Applicant SEED HEALTH INC. Inventor Rajat Dhir

The present invention comprises compositions, systems, and methods of improving the skin and the skin microbiome using bacterial strains and their derivatives, and prebiotics. A useful composition of the invention comprises at least one of (a) a prebiotic that selectively promotes the growth of at least one desirable strain of Cutibacterium acnes (C. acnes); (b) a probiotic comprising at least one desirable strain of C. acnes; and (c) a post-biotic comprising at least one molecule produced by C. acnes.

5.20210128578CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE
US 06.05.2021
Int.Class A61K 31/55
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
Appl.No 17098678 Applicant Nocion Therapeutics, Inc. Inventor Bridget McCarthy Cole

The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof:

embedded image

The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.

6.WO/2021/083879BROMODOMAIN INHIBITORS
WO 06.05.2021
Int.Class A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Appl.No PCT/EP2020/080156 Applicant RHEINISCH-WESTFÄLISCHE TECHNISCHE HOCHSCHULE (RWTH) AACHEN Inventor BOLM, Carsten
The invention relates to compounds according to the general formula (1), to their use for producing a medicament, in particular for the treatment of bromodomain-related diseases, such as cancers.
7.WO/2021/086069COMPOUND COMPRISING EZH2 INHIBITOR AND E3 LIGASE BINDER AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING EZH2-ASSOCIATED DISEASE COMPRISING SAME AS ACTIVE INGREDIENT
WO 06.05.2021
Int.Class C07D 405/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
14containing three or more hetero rings
Appl.No PCT/KR2020/014936 Applicant DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION Inventor YU, Ji-Hoon
The present invention relates to a compound comprising an EZH2 inhibitor and an E3 ligase binder, and a pharmaceutical composition for preventing or treating EZH2-associated disease and a pharmaceutical composition for selectively degrading protein, each containing the compound as an active ingredient. The compound is capable of selectively degrading EZH2, and thus can be usefully applied for treatment of EZH2-associated disease or cancer, specifically a cancer in which EZH2 is overexpressed.
8.WO/2021/083384LOW MOLECULAR WEIGHT CHONDROITIN SULFATE, COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF
WO 06.05.2021
Int.Class C12P 19/14
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
19Preparation of compounds containing saccharide radicals
14produced by the action of a carbohydrase, e.g. by alpha-amylase
Appl.No PCT/CN2020/126003 Applicant NANJING XINLANG ENTERPRISE MANAGEMENT CONSULTING CO.,LTD. Inventor ZHANG, Haoning
Disclosed are a low molecular weight chondroitin sulfate and a preparation method therefor. The method comprises: using a macromolecular chondroitin sulfate as a raw material, and subjecting same to production processes of chondroitin sulfate lyase degradation, deproteinization, filtration, sterilization, drying, etc., so as to obtain a low molecular weight chondroitin sulfate with an average molecular weight less than 1000 daltons. The chondroitin sulfate has a narrow molecular weight distribution range, wherein chondroitin sulfate disaccharides account for 43-60%; chondroitin sulfate tetrasaccharides account for 30-45%; the sum of the content of chondroitin sulfate disaccharides and chondroitin sulfate tetrasaccharides is greater than 87%; the total content of oligosaccharides in the low molecular weight chondroitin sulfate is at least 97%; and the content of protein does not exceed 0.5%. Compared with common commercially available macromolecular chondroitin sulfate, the product has a more obvious repair effect on chondrocytes damaged by 1 mM hydrogen peroxide within the concentration of 50-100 μg/mL. The product has a strong repair ability with a repair rate between 14% and 23%, and can be used to treat joint injuries and is an important raw material for medical products, health care products, cosmetics, foods, etc.
9.WO/2021/086234NOVEL CHEMICAL COMPOUND L-LYSINE 9-OXOACRIDINYL-10-ACETATE
WO 06.05.2021
Int.Class C07D 219/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
219Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
04with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
06Oxygen atoms
Appl.No PCT/RU2020/050289 Applicant SCIENTIFIC TECHNOLOGICAL PHARMACEUTICAL FIRM "POLYSAN" LTD. Inventor KOVALENKO, Alexey Leonidovich
The invention relates to chemistry, pharmaceuticals and medicine, and specifically to a new chemical compound of the class of derivatives of 9-oxoacridinyl-10-acetate: L-lysine 9-oxoacridinyl-10-acetate, which stimulates production of interleukin-24 (IL-24) and tumor necrosis factor beta (TNF-β) and has anti-tumor activity. The invention may be used in anti-tumor therapy, in particular, as an adjuvant in the complex treatment of oncological diseases. The invention addresses the problem of creating a novel chemical compound which stimulates production of the cytokines interleukin-24 and tumor necrosis factor beta and exhibits anti-tumor activity with low toxicity. The stated problem is solved by a novel chemical compound: L-lysine 9-oxoacridinyl-10-acetate of formula (I) or (II).
10.WO/2021/086879COMPOUNDS AND METHODS OF USE
WO 06.05.2021
Int.Class A61K 31/506
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506not condensed and containing further heterocyclic rings
Appl.No PCT/US2020/057601 Applicant TANGO THERAPEUTICS, INC. Inventor COTTRELL, Kevin, M.
Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X1, X2, X3, X4, X5, A, L, R1, R2, R5, m and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.